Politics

Politics

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

By Lev Facher

Politics

House votes to overturn Trump administration ban on fetal tissue research

By Lev Facher and Megan Thielking

Politics

House progressives challenge drug makers to come back to Capitol Hill

By Lev Facher

Politics

Senators want to know if HHS money went to Chinese genomics firms

By Damian Garde

Politics

Stem cell clinics co-opt clinical-trials registry to market unproven therapies, critics say

By Eric Boodman

Politics

A new push aims to bring mental health and addiction into the 2020 campaign conversation

By Megan Thielking

Politics

Fed up with Washington, ALS advocates consider ACT UP’s take-no-prisoners approach

By Nicholas Florko

Politics

Top Senate Republican outlines a path forward for bipartisan drug pricing bill

By Ruth Hailu

Politics

The Trump administration will end fetal tissue research by government scientists

By Damian Garde

Politics

NIH has referred 16 allegations of foreign influence on U.S. research to investigators

By Andrew Joseph

Politics

Congress revives ban on altering the DNA of human embryos used for pregnancies

By Andrew Joseph

Politics

Congress weighs dropping ban on altering the DNA of human embryos used for pregnancies

By Sharon Begley and Andrew Joseph

Politics

At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise

By Nicholas Florko

Special Report

When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans

By Nicholas Florko

Politics

These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent

By Lev Facher

Politics

A new Senate health package includes surprisingly aggressive drug pricing reforms

By Nicholas Florko and Lev Facher

Politics

‘People are just doing it’: Gottlieb says evidence of CBD supplements’ medicinal value is lacking, despite popularity

By Nicholas Florko

Politics

Dude, where’s my regulatory framework? As CBD gains popularity, Washington struggles to keep up

By Nicholas Florko

Politics

Trump administration backs off a proposal to let Medicare plans exclude certain drugs

By Nicholas Florko

Politics

In Washington, a partisan approach to lowering drug costs leaves Democrats doubting their own party leadership

By Lev Facher

Politics

A new study sparks a war of words over the drug industry’s commitment to research

By Nicholas Florko

Vice President Joe Biden Announces He's Not Running For President

Politics

Joe Biden may resurface a long-held dream: a White House laser-focused on cancer

By Lev Facher

Politics

FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic

By Nicholas Florko and Ed Silverman

Politics

Part protest, part survival tactic: How Americans are using pilgrimages to Canada to get cheaper insulin

By Nicholas Florko

Donald Trump speaks prior to signing bills intended to lower prescription drug prices

Politics

Drug makers will have to include prices in TV ads as soon as this summer

By Nicholas Florko

Why Democrats reopened the debate about germline gene editing

Watch: An introduction to CBD — and what Washington might do about it

Inhumane or unavoidable? As Congress scrutinizes an increase in monkey research, scientists defend its necessity

Amgen, Merck, and Eli Lilly sue over Trump administration policy to require drug prices in TV ads

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

House votes to overturn Trump administration ban on fetal tissue research

House progressives challenge drug makers to come back to Capitol Hill

Senators want to know if HHS money went to Chinese genomics firms

Stem cell clinics co-opt clinical-trials registry to market unproven therapies, critics say

A new push aims to bring mental health and addiction into the 2020 campaign conversation

Fed up with Washington, ALS advocates consider ACT UP’s take-no-prisoners approach

Top Senate Republican outlines a path forward for bipartisan drug pricing bill

The Trump administration will end fetal tissue research by government scientists

NIH has referred 16 allegations of foreign influence on U.S. research to investigators

Congress revives ban on altering the DNA of human embryos used for pregnancies

Congress weighs dropping ban on altering the DNA of human embryos used for pregnancies

At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise

When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans

These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent

A new Senate health package includes surprisingly aggressive drug pricing reforms

‘People are just doing it’: Gottlieb says evidence of CBD supplements’ medicinal value is lacking, despite popularity

Dude, where’s my regulatory framework? As CBD gains popularity, Washington struggles to keep up

Trump administration backs off a proposal to let Medicare plans exclude certain drugs

In Washington, a partisan approach to lowering drug costs leaves Democrats doubting their own party leadership

A new study sparks a war of words over the drug industry’s commitment to research

Joe Biden may resurface a long-held dream: a White House laser-focused on cancer

FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic

Part protest, part survival tactic: How Americans are using pilgrimages to Canada to get cheaper insulin

Drug makers will have to include prices in TV ads as soon as this summer

Politics

Sign up for our Daily Recap newsletter